Global Type 1 Diabetes Development Market 2016-2020
"Global
Type 1 Diabetes Market 2016-2020"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
About
Type 1 Diabetes Drugs
Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
Get
Sample
Report
With TOC @
http://www.researchmoz.us/enquiry.php?type=S&repid=685165
Type
2 diabetes (non-insulin-dependent diabetes mellitus): In this
condition, though the body produces the required amount of insulin,
the cells do not respond to it. This results in a high glucose level
in the body.
Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.
Technavios analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Eli Lilly and Company
Novo Nordisk A/S
Sanofi SA
Other prominent vendors
Adocia
Astellas Pharma
AstraZeneca
Baxalta
BHV Pharma
Biocon
Biodel
Boehringer Ingelheim
CureDM
Dance Biopharm
Diamyd Therapeutics AB
Diasome Pharmaceuticals
DiaVac
Exsulin
Gan & Lee Pharmaceuticals
Generex Biotechnology
GlaxoSmithKline
ILTOO Pharma
Intrexon
Islet Sciences
Kamada
Kotobuki Pharmaceutical
Lexicon Pharmaceuticals
Living Cell Technologie
MacroGenics
MannKind Pharmaceuticals
Merck
Merrion Pharmaceutical
Oramed Pharmaceuticals
Osiris Therapeutics
Perle Biosciences
Pfizer
REGiMMUNE
Strongbridge Biopharma
Toleranzia
Tolerio
Xeris Pharmaceuticals
XOMA
Market driver
Increase in prevalence of type 1 diabetes
For a full, detailed list, view our report
Market challenge
Poor storage conditions and distribution policies for insulin
For a full, detailed list, view our report
Market trend
Awareness programs and initiatives
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.
Technavios analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Eli Lilly and Company
Novo Nordisk A/S
Sanofi SA
Other prominent vendors
Adocia
Astellas Pharma
AstraZeneca
Baxalta
BHV Pharma
Biocon
Biodel
Boehringer Ingelheim
CureDM
Dance Biopharm
Diamyd Therapeutics AB
Diasome Pharmaceuticals
DiaVac
Exsulin
Gan & Lee Pharmaceuticals
Generex Biotechnology
GlaxoSmithKline
ILTOO Pharma
Intrexon
Islet Sciences
Kamada
Kotobuki Pharmaceutical
Lexicon Pharmaceuticals
Living Cell Technologie
MacroGenics
MannKind Pharmaceuticals
Merck
Merrion Pharmaceutical
Oramed Pharmaceuticals
Osiris Therapeutics
Perle Biosciences
Pfizer
REGiMMUNE
Strongbridge Biopharma
Toleranzia
Tolerio
Xeris Pharmaceuticals
XOMA
Market driver
Increase in prevalence of type 1 diabetes
For a full, detailed list, view our report
Market challenge
Poor storage conditions and distribution policies for insulin
For a full, detailed list, view our report
Market trend
Awareness programs and initiatives
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Comments
Post a Comment